CroupEx Sprinkles
- Manufacturer
- Feelgood Health | W.Last
- Effective date
- 2010-07-22
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 6
- Source
- full-release
- Hydrated at
- 2026-06-01 02:02:36
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - PURPOSE SECTION
Relieves croup and barking cough
INDICATIONS & USAGE SECTION
Indications: Homeopathic remedy for dry, barking cough in children.
DOSAGE & ADMINISTRATION SECTION
Dosage: 1 pinch onto the tongue every 20 minutes. Children 1-12 years may use together with Congesto-K KiddieRub™ for combined support.
GENERAL PRECAUTIONS SECTION
Caution: If symptoms persist or worsen, a health care professional should be consulted.Keep this and all medicines from the reach of children.
OTC - ACTIVE INGREDIENT SECTION
Ingredients: Each dose contains equal parts of Aconitum nap (30C) (HPUS), Hepar sulph calc (6C) (HPUS), Kali mur (6X) (HPUS), Mag phos (6X) (HPUS), Rumex crisp (6C) (HPUS)
INACTIVE INGREDIENT SECTION
Sucrose (inactive ingredient).
PREGNANCY SECTION
If pregnant or breastfeeding, ask a health professional before use.
WARNINGS SECTION
Contains no gluten, artificial flavors, colors or preservatives. Safe for all ages and during pregnancy.
INFORMATION FOR PATIENTS SECTION
All Native Remedies health products are especially
formulated by experts in the field of natural health and are manufactured
according to the highest pharmaceutical standards for maximum safety and
effectiveness. For more information, visit us at
www.nativeremedies.com
Distributed by
Native Remedies, LLC
6531 Park of Commerce Blvd.
Suite 160
Boca Raton, FL 33487
Phone: 1.877.289.1235
International: + 1.561.999.8857
The letters HPUS indicate that the component(s) in this product is (are) officially monographed in the Homeopathic Pharmacopoeia of the United States.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep this and all medicines from the reach of children.
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68647-106-10 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-cb67-621f-e053-dbdaa90a74ad | CROUPEX SPRINKLES |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68647-106-10 | CroupEx Sprinkles | 20000 mg in 1 BOTTLE, GLASS | GRANULE | 20000 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68647-106 | CROUPEX SPRINKLES (ACONITUM NAP , HEPAR SULPH CALC , KALI MUR , MAG PHOS , RUMEX CRISP , SUCROSE ) GRANULE [FEELGOOD HEALTH] | 6 | Legacy NDC, 1 package rows | 20100921_2101c379-8848-4e56-969f-c0309fbe9c9d.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACONITUM NAPELLUS | ACTIVE INGREDIENT | U0NQ8555JD | 6 | |
| CALCIUM SULFIDE | ACTIVE INGREDIENT | 1MBW07J51Q | 6 | |
| MAGNESIUM PHOSPHATE | ACTIVE INGREDIENT | 453COF7817 | 6 | |
| POTASSIUM CHLORIDE | ACTIVE INGREDIENT | 660YQ98I10 | 6 | |
| RUMEX CRISPUS POLLEN | ACTIVE INGREDIENT | V825XJG64G | 6 | |
| ACONITUM NAPELLUS | ACTIVE MOIETY | U0NQ8555JD | 6 | |
| CALCIUM CATION | ACTIVE MOIETY | 2M83C4R6ZB | 6 | |
| MAGNESIUM CATION | ACTIVE MOIETY | T6V3LHY838 | 6 | |
| POTASSIUM CATION | ACTIVE MOIETY | 295O53K152 | 6 | |
| RUMEX CRISPUS POLLEN | ACTIVE MOIETY | V825XJG64G | 6 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 6 |
Products#
Every source-derived product name is available through these pages.
- CroupEx Sprinkles
- Aconitum nap , Hepar sulph calc , Kali mur , Mag phos , Rumex crisp , Sucrose
- ACONITUM NAPELLUS
- CALCIUM SULFIDE
- CALCIUM CATION
- POTASSIUM CHLORIDE
- POTASSIUM CATION
- MAGNESIUM PHOSPHATE
- MAGNESIUM CATION
- RUMEX CRISPUS POLLEN
- SUCROSE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68647-106 | 68647-106-10 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ACONITUM NAPELLUS | U0NQ8555JD | ACTIB |
| CALCIUM SULFIDE | 1MBW07J51Q | ACTIB |
| POTASSIUM CHLORIDE | 660YQ98I10 | ACTIB |
| MAGNESIUM PHOSPHATE | 453COF7817 | ACTIB |
| RUMEX CRISPUS POLLEN | V825XJG64G | ACTIB |
| SUCROSE | C151H8M554 | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e024f096-2285-44bc-a0ba-fcc36297f7c3 | 2101c379-8848-4e56-969f-c0309fbe9c9d | 2010-07-22 | Warnings | e024f096-2285-44bc-a0ba-fcc36297f7c3 2101c379-8848-4e56-969f-c0309fbe9c9d |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
